Life-changing therapies

Innovative medicines pipeline
Macrocycle discovery platform
Collaborate with Polyphor

Latest news

• Polyphor awarded grant from CARB-X of up to $5.6M to support development of novel antibiotic against multi-drug resistant Gram-negative pathogens

• Polyphor announces positive results from the FDA Type B Guidance meeting on the planned Phase III study for balixafortide

See all news

Meet us at

May 20-22, 2019	UBS Global Healthcare Conference, New York
February 25-26, 2019	12th Annual European Life Science CEO Forum, Zurich

Event calendar

Innovative medicines pipeline

Antibiotics

Murepavadin (POL7080) – Pseudomonas infections

Phase III

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

OMPTA platform –  targeting Gram-negative resistant pathogens

Lead preclinical compound: POL7306

 

Preclinical

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

CXCR4 antagonist

Balixafortide (POL6326) – for novel immune-oncology agent for combination therapy

Fast Track Designation granted by FDA

Phase III

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

Inhaled elastase inhibitor

POL6014 – Cystic Fibrosis

Outlicensed to Santhera Pharmaceuticals 14.02.2018

Phase I

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

Macrocycle discovery platform

New modalities to address challenging biological targets

Learn more